<DOC>
	<DOC>NCT00174382</DOC>
	<brief_summary>To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.</brief_summary>
	<brief_title>Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia</brief_title>
	<detailed_description>The trial was terminated on October 15, 2007 due to difficulties in recruiting the subjects. There were no safety or efficacy concerns regarding the study medication in the decision to terminate the trial.</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia, Vascular</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Subjects must meet DSMIVTR criteria for the clinical diagnosis of Vascular Dementia or the clinical diagnosis of dementia due to multiple etiologies. Subjects must have a reliable caregiver or family member who agrees to accompany the subject to all scheduled visits, provide information about the subject as required. Subjects with any current primary psychiatric diagnosis other than dementia of the Alzheimer's type or Vascular Dementia.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>